Cargando…
Antibody–Drug Conjugates for Cancer Therapy
Antibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on...
Autores principales: | Parslow, Adam C., Parakh, Sagun, Lee, Fook-Thean, Gan, Hui K., Scott, Andrew M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344263/ https://www.ncbi.nlm.nih.gov/pubmed/28536381 http://dx.doi.org/10.3390/biomedicines4030014 |
Ejemplares similares
-
Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020) -
Antibody-drug conjugates: beyond current approvals and potential future strategies
por: Menon, Siddharth, et al.
Publicado: (2022) -
Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
por: Parakh, Sagun, et al.
Publicado: (2021) -
Radiolabeled Antibodies for Cancer Imaging and Therapy
por: Parakh, Sagun, et al.
Publicado: (2022) -
Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma
por: Chia, Puey-Ling, et al.
Publicado: (2020)